AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$PTCT

Boulding Mark Elliott sold $204K of PTCT

Boulding Mark Elliott (EXEC. VP AND CLO) sold 2,813 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $72.57 ($72.39–$72.90, $0.20M total) across 2 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boulding Mark Elliott
Published Aug 19, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTCT
Neutral
medium confidence
Mentioned
$PTCT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTCTNeutralLow
01

Why it matters

The transaction reduces Elliott's ownership to 105,272 shares, a modest change that may cause slight short‑term bearish sentiment but is unlikely to move the stock significantly.

02

Market read

Primary relevance is to PTCT shareholders; broader market impact is negligible.

03

What to watch

Potential upcoming clinical trial results or financing events not disclosed may be the real driver of stock movement.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-19 after market close

Background

Form 4 filing by PTC Therapeutics executive VP and CLO Mark Elliott details a 10b5-1 pre‑arranged open‑market sale of 2,813 shares at an average price of $72.57.

Company-level read

Ticker impact

$PTCTNeutralMedium confidence
Context

SEC Form 4 shows executive VP Mark Elliott sold 2,813 shares for $204,127, reducing his stake to 105,272 shares.

Expected impact

Potential short-term pressure on PTCT stock, limited to a few percent.

Evidence & confidence

Sale amount is under $1M and represents a small percentage of holdings; market may view it as routine.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and not sector-defining.

Regional

No regional effect; company is US-listed biotech.

Global

Limited global relevance; only affects PTCT investors.

Counterpoint

What could challenge this read

The sale could be unrelated to confidence and merely a liquidity event under a 10b5-1 plan.

Key entities

  • Company
    PTC Therapeutics, Inc.

    US‑listed biotech firm (ticker PTCT) subject of the insider sale.

  • Executive
    Mark Elliott

    Executive Vice President and Chief Legal Officer of PTCT, insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTCT insider trading history →

Related articles

AUG 27
$PTCTMedAI 8/10

Broader Sephience PKU Data Could Be A Game Changer For PTC Therapeutics (PTCT)

PTC Therapeutics (PTCT) presented new data on its PKU therapy Sephience at the 2026 SSIEM Symposium, showing benefits in lowering phenylalanine levels and diet liberalization across a broad PKU population. The data suggest Sephience could be relevant for a wider spectrum of PKU severity. PTC raised its full-year revenue guidance to US$1.18 billion to US$1.28 billion following stronger Q2 2026 results. Analysts have varying opinions on the company's future revenue and earnings, with some predicti

simplywall.st3 min
AUG 24
$PTCTMedAI 8/10

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics (NASDAQ: PTCT) announced new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile for PKU patients. Data include significant blood Phe reductions and benefits across patient subgroups. Sephience is approved in the U.S., EU, Japan, and other regions for PKU treatment.

morningstar.com2 min
AUG 24
$PTCTMedAI 8/10

PTC presents Sephience data at metabolic disorders symposium

PTC Therapeutics (PTCT) presented data on Sephience at a metabolic disorders symposium. Clinical trials and real-world data showed significant reductions in blood phenylalanine levels and dietary liberalization in PKU patients. Sephience is approved in the U.S., EU, and Japan. The drug carries warnings about bleeding risk and hypophenylalaninemia. PKU affects about 58,000 people globally.

investing.com2 min
AUG 24
$PTCTMedAI 8/10

PTC Wins Sangamo's Fabry Gene Therapy in Bankruptcy Auction

PTC Therapeutics won a bankruptcy auction for Sangamo Therapeutics' Fabry disease gene therapy, ST-920, paying $111M upfront and up to $100M in milestones. PTC outbid Astellas and TerSera. The deal requires court and regulatory approval. ST-920 showed positive clinical data, supporting an accelerated FDA approval pathway. Eli Lilly also acquired other Sangamo assets for $50M.

cgtlive.com3 min
AUG 13
$PTCTMedAI 9/10

PTC Expands Rare Disease Portfolio With ST-920 Acquisition

PTC Therapeutics (PTCT) agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million upfront plus milestones. PTC cites Phase 1/2 STAAR data and plans an accelerated approval BLA submission, with CMC due Q4 2026 and a 2027 launch. Close expected in Q3 2026.

rttnews.com4 min